Ocular Therapeutix's current wet AMD treatment is dominated by anti-VEGF drugs, with EYLEA holding a 63% global market share in 2024. Read why OCUL stock is a sell.

In the spring of 1976, the year America turned 200, Jan Randall, now Jan Crollard, stood under hot stage lights at Pioneer Middle School with a speech about “tomorrow” in ...

Have you ever lost a Word document due to an unexpected PC crash? Just this week, I experienced this firsthand. Hours of work vanished when my document disappeared. I didn’t panic, though, because my ...

A recent US Supreme Court victory for retirement investors that lowered the bar for bringing certain ERISA claims is becoming a blessing in disguise for employers seeking to escape litigation.